DEF 14A: Humacyte Sets Date for 2024 Annual Stockholders Meeting, Board to Rebalance Classes

Humacyte, Inc. announces its annual meeting of stockholders to be held virtually on June 11, 2024, with key proposals including the election of directors and ratification of the company's independent accounting firm.

Summary

• Humacyte, Inc. will hold its Annual Meeting of Stockholders virtually on June 11, 2024, at 8:00 a.m. Eastern Time.
• Stockholders of record as of April 24, 2024, are entitled to vote at the meeting.
• The meeting will address the election of six Class III directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024, and any other business properly brought before the meeting.
• The Board of Directors is recommending stockholders vote in favor of all director nominees and the ratification of PwC.
• Two directors, Gordon Binder and Rajiv Shukla, will resign from the Board, effective as of the date of the Annual Meeting.
• The Board intends to rebalance the classes of directors by moving Drs. Bamforth and Jones from Class III to Class II, with a term expiring at the 2026 annual meeting of stockholders.
• Following the Annual Meeting, the Board intends to reduce the size of the Board to 12 members.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the routine nature of the announcements and the Board's recommendations.

Positives

• The company is providing convenient access to the Annual Meeting by holding it virtually.
• Stockholders have multiple options for voting, including online, telephone, and mail.
• The Board is recommending experienced and qualified individuals for election as directors.
• The Audit Committee recommends the reappointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm.

Negatives

• Two directors, Gordon Binder and Rajiv Shukla, will resign from the Board, effective as of the date of the Annual Meeting.

Risks

• If stockholders fail to ratify the selection of PwC, the Audit Committee and the Board will reconsider whether or not to retain PwC.
• Unexpected occurrences could make nominees unavailable for election, requiring votes for substitute nominees.

Future Outlook

The company is preparing for a potential market launch of the HAV in the vascular trauma indication.

Management Comments

• Laura E. Niklason, President, Chief Executive Officer and Director: 'You are cordially invited to attend the Annual Meeting of Stockholders'.
• The Board believes that planning for CEO succession is an important responsibility and periodically discusses the CEO succession plan to help ensure business continuity.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the solicitation of proxies, election of directors, and appointment of auditors.

Comparison to Industry Standards

• The director compensation policy, including annual retainers and equity grants, appears to be in line with industry standards for similarly sized biopharmaceutical companies.
• The use of a virtual-only format for the annual meeting is becoming increasingly common, reflecting a trend towards greater accessibility and cost-effectiveness.
• The company's approach to risk oversight, involving both the full Board and its committees, is consistent with best practices in corporate governance.

Management Changes

Corporate Governance

Legal Proceedings

• As of the filing of this Proxy Statement, there are no legal proceedings, and during the past ten years there have been no legal proceedings, that are material to the ability or integrity of any of our directors, director nominees or executive officers.

Related Party Transactions

• In May 2022 and June 2023, the company entered into three services agreements with Frenova Renal Research (Frenova), a subsidiary of Fresenius Medical Care, to conduct a study to review the outcomes of 178,575 adult patients who received in-center dialysis at Fresenius Kidney Care dialysis centers.
• The company paid approximately $350,000 and $138,000 during the years ended December 31, 2023 and 2022, respectively, for clinical research services performed by Frenova.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's governance and direction.
• Employees are affected by the company's compensation policies and equity incentive plans.
• The company's relationship with Fresenius Medical Care impacts its distribution and research activities.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and report final results in a Current Report on Form 8-K.
• The Board will continue to monitor and evaluate its corporate governance practices.

Key Dates

Keywords

Annual Meeting, Stockholders, Board of Directors, Proxy Statement, Director Election, PricewaterhouseCoopers, Corporate Governance, Humacyte